AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Rhea-AI Summary

AIM ImmunoTech (NYSE:AIM) has reported its Q2 2025 financial results and provided updates on its pipeline programs. The company's primary focus remains on its Phase 2 DURIPANC trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for pancreatic cancer treatment, which has shown promising signs regarding toxicity, progression-free survival (PFS), and overall survival (OS).

The company recently raised $8.0 million through a public offering in July 2025, extending its operational runway for approximately 12 months. Financial results show a net loss of $2.8 million ($3.68 per share) for Q2 2025, compared to $1.8 million ($3.00 per share) in Q2 2024. Cash position stood at $835,000 as of June 30, 2025.

Positive

• Positive mid-year data from Phase 2 DURIPANC study showing promising survival rates and no significant toxicity
• Successfully raised $8.0 million in gross proceeds through public offering
• Resumed trading on NYSE American
• Reduced general and administrative expenses to $1.5M from $2.6M year-over-year

Negative

• Net loss increased to $2.8M from $1.8M year-over-year
• Low cash position of $835,000 as of June 30, 2025
• Loss per share increased to $3.68 from $3.00 year-over-year

Insights

Clinical Oncology Researcher

AIM's pancreatic cancer therapy shows promising survival data amid financial challenges, with recent funding extending runway by 12 months.

The mid-year update from AIM ImmunoTech's Phase 2 DURIPANC study provides encouraging signals in one of oncology's most challenging indications. The combination of Ampligen (rintatolimod) with AstraZeneca's Imfinzi (durvalumab) is demonstrating both safety (no significant toxicity) and potential efficacy advantages in progression-free survival (PFS) and overall survival (OS) for pancreatic cancer patients. This is particularly noteworthy given pancreatic cancer's notoriously poor response to immunotherapies as monotherapies.

The study specifically targets metastatic pancreatic cancer patients with stable disease following FOLFIRINOX treatment, representing a strategic approach to leverage the immunomodulatory properties of Ampligen in potentially sensitizing these difficult tumors to checkpoint inhibition. The immunological rationale behind this combination is sound—Ampligen, as a TLR3 agonist, may help transform the typically "cold" pancreatic tumor microenvironment into one more responsive to anti-PD-L1 therapy.

While the data appears promising, investors should note that this represents a mid-year update rather than final results, and the press release doesn't provide specific numerical data on survival improvements or statistical significance. The upcoming presentations at scientific meetings may provide more granular efficacy data needed for comprehensive evaluation. The fact that the data was compelling enough to be accepted at multiple scientific congresses, including the American Association of Immunologists meeting, does suggest legitimate scientific interest in these findings.

Biotech Financial Analyst

AIM's $8M offering provides 12-month runway amid $2.8M quarterly loss; positive clinical signals balanced against financial constraints.

AIM ImmunoTech's financial position reveals both promise and challenges. The company raised $8 million in gross proceeds from a July 2025 public equity offering, which management indicates will fund operations for approximately 12 months. This funding extension is critical given the company's limited cash reserves of just $835,000 as of June 30, 2025.

The quarterly loss widened to $2.8 million ($3.68 per share) compared to $1.8 million ($3.00 per share) in Q2 2024, representing a 55.6% increase in net loss. However, the company did manage to reduce general and administrative expenses by 42.3% to $1.5 million from $2.6 million in the comparable period.

Research and development expenses remained relatively stable at $1.2 million, up slightly from $1.1 million in Q2 2024, indicating continued investment in their clinical programs despite financial constraints. At the current burn rate of approximately $2.8 million per quarter, the $8 million raise indeed provides around 12 months of operational runway, assuming no significant increase in expenses.

The company's return to NYSE American listing is a positive development for liquidity and investor access. However, the substantial per-share losses and limited cash reserves prior to the July offering highlight the precarious financial position typical of small-cap biotech companies with promising but still-developing clinical assets. Future capital needs will likely be determined by clinical progress and potential partnership opportunities around their pancreatic cancer program.

Continued progress across pipeline programs with focus on pancreatic cancer

Mid-year report of Ampligen^® (rintatolimod) in combination with AstraZeneca’s Imfinzi^® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS

Bolstered cash position provides runway to fund operations for approximately 12 months

OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2025.

“Through the second quarter, we continued to prioritize and accelerate our development efforts for Ampligen, particularly in our Phase 2 trial for locally advanced pancreatic cancer in collaboration with Erasmus Medical Center and AstraZeneca. We remain encouraged by the growing body of positive clinical data demonstrated to date and believe that as we build momentum, we are well positioned to execute on a clear path toward government approval. Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers, and our mission remains focused on making a meaningful difference in this space for patients,” commented AIM Chief Executive Officer Thomas K. Equels.

Recent Highlights

• Resumed trading on the NYSE American;
• Closed public equity offering in July, raising $8.0 million in gross proceeds, which is expected to fund operations for approximately 12 months;
• Reported positive data in a mid-year update from the ongoing Phase 2 DURIPANC clinical study evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX (See: NCT05927142);
• Announced upcoming presentations at the International 5^th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care;
• Ampligen oncology data was presented at scientific congresses including the Annual Meeting of the American Association of Immunologists and U.S.-Poland Science and Technology Symposium 2025.
  
  

For more information, please visit the Company’s website at aimimmuno.com.

Summary of Financial Highlights for Second Quarter 2025

• As of June 30, 2025, AIM reported cash, cash equivalents and marketable investments of $835,000.
• Research and development expenses for the three months ended June 30, 2025 were $1.2 million, compared to $1.1 million for the same period in 2024.
• General and administrative expenses were $1.5 million for the three months ended June 30, 2025, compared to $2.6 million for the same period 2024.
• The net loss from operations for the three months ended June 30, 2025 was $2.8 million, or $(3.68) per share, compared to $1.8 million, or $(3.00) per share, for the three months ended June 30, 2024.

Please refer to the full 10-Q for complete details.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Publication of data, and pre-clinical and clinical success seen to date, does not guarantee that Ampligen will be approved for commercial treatment in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

What were AIM ImmunoTech's (AIM) Q2 2025 financial results?

AIM reported a net loss of $2.8 million ($3.68 per share) and cash position of $835,000. R&D expenses were $1.2M and G&A expenses were $1.5M for Q2 2025.

How much did AIM ImmunoTech raise in its July 2025 public offering?

AIM raised $8.0 million in gross proceeds through a public offering in July 2025, which is expected to fund operations for approximately 12 months.

What are the latest developments in AIM's pancreatic cancer trial?

The Phase 2 DURIPANC trial evaluating Ampligen with AstraZeneca's Imfinzi showed promising signs of both no significant toxicity and superior PFS and OS in pancreatic cancer treatment.

What is the current status of AIM ImmunoTech's stock listing?

AIM ImmunoTech has resumed trading on the NYSE American stock exchange.

How long will AIM ImmunoTech's current funding last?

The company's recent $8.0 million public offering is expected to provide an operational runway for approximately 12 months.